: The Thailand HIV/AIDS and Infectious Disease Clinical Trials Unit (THAI CTU) Is the renamed renewal of Chiang Mai University HIV/AIDS Clinical Trials Unit- Sirisanthana, Thira (Grant# U01 Al 069399, Feb 2007-Jan 2014), which expands beyond the Chiang Mai University Research Institute for Health Sciences (CMU-RIHES) to add the experience and resources of another major HIV research institution: the Thai Red Cross AIDS Research Centre (TRC-ARC), affiliated with Chulalongkorn University.
The aim of the THAI CTU Is to collaborate with five Clinical Research Networks established by NIAID, NIH under RFA-AI-12-001, -004, -008, -011, and -012, in coordinating and executing clinical research in Thailand and the neighboring region to expand knowledge and improve treatment and prevention of HIV and related Infectious diseases. It also aims to assist the CRNs In refining their research agendas to meet the needs, priorities, circumstances, and sensitivities of low- and middle-income countries in hosting research studies, so that findings are of utility fo preventing and treating HIV and related conditions both universally, as well as in the country of research. Located in the cities of Chiang Mai and Bangkok, Thailand, the THAI CTU is led by Co-Principal Investigators Suwat Chariyalertsak and Kiat Ruxrungtham, plus P. Phanuphak, T. Sirisanthana, K. Supparatpinyo, G.J.P.(F) van Griensven, V. Sirisanthan, A. Avihingsanon, T. Puthanakit, and K. Srithanaviboonchal. It is comprised of four Clinical Research Sites which will implement clinical and related HIV studies on maternal, pediatric, and adult therapeutics, on topical microbicides to prevent HIV transmission, on Integrated population-based prevention strategies, and on vaccines. After appropriate community and ethical approvals, such studies will be conducted on volunteers from populations with both high and usual risk for HIV, including those seeking voluntary counseling and testing or healthcare, men who have sex with men and transgender women, HIV-discordant couples, persons who inject drugs, pregnant, neonates, children, adolescents, blood donors, and persons from the general population.
Enlightened prevention programs reduced HIV transmission in Thailand, a beachhead for the explosive arrival of HIV into Asia in the 1980s. However, new infections remain unacceptably frequent. Thai Institutions as RIHES and TRC-ARC provide infrastructure, population access, and indigenous scientific expertise and leadership for valuable clinical research of global, regional, and local application in controlling the epidemic.
|Carballo-Diéguez, Alex; Balán, Ivan C; Brown 3rd, William et al. (2017) High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women. PLoS One 12:e0181607|
|Cranston, Ross D; Lama, Javier R; Richardson, Barbra A et al. (2017) MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel. Clin Infect Dis 64:614-620|
|Greer, Amy E; Ou, San-San; Wilson, Ethan et al. (2017) Comparison of Hepatitis B Virus Infection in HIV-Infected and HIV-Uninfected Participants Enrolled in a Multinational Clinical Trial: HPTN 052. J Acquir Immune Defic Syndr 76:388-393|
|Palumbo, Philip J; Wilson, Ethan A; Piwowar-Manning, Estelle et al. (2017) Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052. PLoS One 12:e0177281|
|Celum, Connie; Hong, Ting; Cent, Anne et al. (2017) Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study. J Infect Dis 215:907-910|
|Salazar-Austin, N; Kulich, M; Chingono, A et al. (2017) Age-Related Differences in Socio-demographic and Behavioral Determinants of HIV Testing and Counseling in HPTN 043/NIMH Project Accept. AIDS Behav :|
|Currier, Judith S; Britto, Paula; Hoffman, Risa M et al. (2017) Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 ? 400 cells/mm3. PLoS One 12:e0176009|
|Singini, Isaac; Campbell, Thomas B; Smeaton, Laura M et al. (2016) Predictors of late virologic failure after initial successful suppression of HIV replication on efavirenz-based antiretroviral therapy. HIV Clin Trials :1-8|
|Grant, Robert M; Sevelius, Jae M; Guanira, Juan V et al. (2016) Transgender Women in Clinical Trials of Pre-Exposure Prophylaxis. J Acquir Immune Defic Syndr 72 Suppl 3:S226-9|
|Mathad, Jyoti S; Gupte, Nikhil; Balagopal, Ashwin et al. (2016) Sex-Related Differences in Inflammatory and Immune Activation Markers Before and After Combined Antiretroviral Therapy Initiation. J Acquir Immune Defic Syndr 73:123-9|
Showing the most recent 10 out of 37 publications